A first-in-human study of EPZ-5676 (now termed Pinometostat) is currently in a phase I trial in adults with AML and ALL with rearrangements of the MLL gene (ClinicalTrials.gov identifier: NCT01684150). The gene discussed is KMT2A; the disease is acute myeloid leukemia.